Zhenhuan Cao

431 total citations
28 papers, 289 citations indexed

About

Zhenhuan Cao is a scholar working on Epidemiology, Hepatology and Immunology. According to data from OpenAlex, Zhenhuan Cao has authored 28 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Epidemiology, 23 papers in Hepatology and 7 papers in Immunology. Recurrent topics in Zhenhuan Cao's work include Hepatitis B Virus Studies (23 papers), Hepatitis C virus research (22 papers) and Liver Disease Diagnosis and Treatment (10 papers). Zhenhuan Cao is often cited by papers focused on Hepatitis B Virus Studies (23 papers), Hepatitis C virus research (22 papers) and Liver Disease Diagnosis and Treatment (10 papers). Zhenhuan Cao collaborates with scholars based in China, United States and Hong Kong. Zhenhuan Cao's co-authors include Junfeng Lu, Xinyue Chen, Lina Ma, Yali Liu, Yi Jin, Chengli Shen, Shan Ren, Zhimin He, Xinyue Chen and Meng Sha and has published in prestigious journals such as PLoS ONE, Hepatology and Journal of Hepatology.

In The Last Decade

Zhenhuan Cao

25 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenhuan Cao China 8 233 207 48 31 22 28 289
Ahmed F. Sherief Egypt 7 167 0.7× 165 0.8× 54 1.1× 8 0.3× 11 0.5× 20 246
G. Fiordalisi Italy 7 241 1.0× 219 1.1× 106 2.2× 17 0.5× 44 2.0× 9 336
Simon B. Larsson Sweden 11 321 1.4× 288 1.4× 38 0.8× 10 0.3× 16 0.7× 27 376
Arthur Y Kim United States 7 118 0.5× 113 0.5× 35 0.7× 11 0.4× 25 1.1× 11 186
Dianhui Tan China 7 270 1.2× 268 1.3× 13 0.3× 39 1.3× 3 0.1× 10 328
M. Aragri Italy 6 96 0.4× 88 0.4× 33 0.7× 19 0.6× 15 0.7× 13 155
Zu‐Jiang Yu China 9 111 0.5× 104 0.5× 30 0.6× 21 0.7× 4 0.2× 15 184
M Ruíz-Moreno Spain 13 414 1.8× 402 1.9× 31 0.6× 18 0.6× 11 0.5× 22 468
Jenny Bischoff Germany 9 139 0.6× 97 0.5× 52 1.1× 40 1.3× 5 0.2× 19 240
Lorenzo Piermatteo Italy 9 137 0.6× 125 0.6× 75 1.6× 7 0.2× 5 0.2× 26 225

Countries citing papers authored by Zhenhuan Cao

Since Specialization
Citations

This map shows the geographic impact of Zhenhuan Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenhuan Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenhuan Cao more than expected).

Fields of papers citing papers by Zhenhuan Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenhuan Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenhuan Cao. The network helps show where Zhenhuan Cao may publish in the future.

Co-authorship network of co-authors of Zhenhuan Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenhuan Cao. A scholar is included among the top collaborators of Zhenhuan Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenhuan Cao. Zhenhuan Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Daobin, et al.. (2024). Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study. World Journal of Gastrointestinal Oncology. 16(12). 4625–4635.
2.
Liu, Yisi, Shan Ren, Lina Ma, et al.. (2024). Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function. Virology Journal. 21(1). 77–77. 4 indexed citations
3.
Liu, Yisi, Xiao Lin, Hong Li, et al.. (2023). Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure. The Brazilian Journal of Infectious Diseases. 27(6). 103703–103703. 2 indexed citations
4.
Liu, Xiaohui, Shuang Zhang, Zhenhuan Cao, et al.. (2023). MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population. Frontiers in Endocrinology. 14. 1199429–1199429. 8 indexed citations
5.
Liu, Yisi, Xiao Lin, Zhenhuan Cao, et al.. (2023). Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha. BMC Endocrine Disorders. 23(1). 115–115. 4 indexed citations
6.
Song, Aixin, Yisi Liu, Zhenhuan Cao, et al.. (2022). Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection. Frontiers in Immunology. 13. 881321–881321. 7 indexed citations
7.
Li, Hong, Xiao Lin, Lili Liu, et al.. (2022). Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers. Frontiers in Immunology. 13. 864354–864354. 2 indexed citations
8.
Lin, Xiao, Hong Li, Junfeng Lu, et al.. (2022). Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance. Frontiers in Immunology. 13. 1028921–1028921. 3 indexed citations
9.
Lin, Xiao, Aixin Song, Junfeng Lu, et al.. (2022). Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. Frontiers in Immunology. 13. 879835–879835. 5 indexed citations
10.
Li, Hong, Lili Liu, Yali Liu, et al.. (2022). Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon. Frontiers in Immunology. 13. 1091786–1091786. 6 indexed citations
11.
Lin, Xiao, Jingyue Wang, Xiaomo Wang, et al.. (2021). Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Annals of Translational Medicine. 9(17). 1365–1365. 6 indexed citations
12.
Song, Aixin, Xiao Lin, Junfeng Lu, et al.. (2021). Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. Frontiers in Immunology. 12. 779347–779347. 21 indexed citations
13.
Cao, Zhenhuan, Lianchun Liang, Haibo Wang, et al.. (2020). Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS ONE. 15(6). e0234764–e0234764. 44 indexed citations
14.
Cao, Zhenhuan, et al.. (2020). B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy. PLoS ONE. 15(12). e0242559–e0242559. 3 indexed citations
15.
Liu, Yali, Junfeng Lu, Zhenhuan Cao, et al.. (2019). Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance. Clinical Gastroenterology and Hepatology. 18(2). 514–516.e2. 43 indexed citations
16.
17.
Cao, Zhenhuan, Yali Liu, Lina Ma, et al.. (2017). A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha. Hepatology. 66(4). 1058–1066. 81 indexed citations
18.
Lu, Junfeng, Yali Liu, Shan Ren, et al.. (2015). Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS ONE. 10(11). e0141072–e0141072. 1 indexed citations
19.
Chen, Xinyue, Zhenhuan Cao, Yali Liu, et al.. (2011). Potent hepatitis B surface antigen response to treatment of hepatitis‐B‐e‐antigen‐positive chronic hepatitis B with α‐interferon plus a nucleos(t)ide analog. Journal of Gastroenterology and Hepatology. 27(3). 481–486. 15 indexed citations
20.
Li, Haiying, Xinyue Chen, Xia Jin, et al.. (2009). Proliferation, But Not Interleukin 2 Production, of Gag-Specific CD8+ T Cells Is Associated With Low HIV Viremia and High CD4 Counts in HIV-1-Infected Chinese Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 52(1). 1–8. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmed F. Sherief Breakdown of academic impact, for papers by G. Fiordalisi Breakdown of academic impact, for papers by Simon B. Larsson Breakdown of academic impact, for papers by Arthur Y Kim Breakdown of academic impact, for papers by Dianhui Tan Breakdown of academic impact, for papers by M. Aragri Breakdown of academic impact, for papers by Zu‐Jiang Yu Breakdown of academic impact, for papers by M Ruíz-Moreno Breakdown of academic impact, for papers by Jenny Bischoff Breakdown of academic impact, for papers by Lorenzo Piermatteo
Rankless by CCL
2026